medigraphic.com
ISSN 0016-3813 (Print)

2004, Number S2

<< Back Next >>

Gac Med Mex 2004; 140 (S2)

HCV infection and hepatic steatosis

Bosques-Padilla F

Language: Spanish
References: 26
Page: 73-76
PDF size: 563.79 Kb.


ABSTRACT

The mechanism by which hepatitis C virus (HCV) causes chronic, progressive liver damage is unknown. Factors other than the virus itself have been implicated. The role of liver steatosis has been recently studied. Hepatic steatosis is a common histologic finding occurring in › 50% of patients with chronic hepatitis C. Both host and viral factors have been demonstrated to play an important role in its development. In patients infected with genotype 1, steatosis appears due to co-existence of Non-alchoholic steatohepatitis (NASH) with HCV and associated with increased body mass index (BMI). Some recent observations suggest that steatosis may be of viral origin and related to genotype 3. This fact raises the possibility of a direct effect of specific viral sequences on the pathogenesis of lipid accumulation. Furthermore, hepatic steatosis attributed to genotype 3 correlates directly with serum and intrahepatic titers of HCV RNA. Resolution of steatosis after successful antiviral therapy as well as steatosis being a sign of recurrent HCV infection in patients with genotype 3 add convincing evidence that steatosis is viral-related. The pathogenic mechanism induced by genotype 3 is speculative. Correlation between steatosis, intrahepatic HCV RNA, and core protein expression suggest a direct effect. Further support is provided by the finding that HCV core protein induces steatosis in transgenic mice. Another possibility relates to interaction with hepatic triglyceride turnover. In conclusion, for patients infected with genotype 1 BMI plays a role in the pathogenesis of steatosis, while in those infected with genotype 3 steatosis may be due to a virusspecific cytopathic effect. Regardless of etiology, the contribution of both to liver fibrosis progression appears to be accepted.


REFERENCES

  1. Niederau C, Lange S, Heintges T, Erhadt A, Buschlamp M, Hurter D, Nawrocki M, Kruska L, Hensel F, Petry W, Haussinger D. Progression of chronic hepatitis C: results of a large prospective cohort study. Hepatology 1998;28:1687-95.

  2. Ramalho F, Costa A, Pires A, Cabrila P, Serejo F, Correia AP, Fatela N, Cloria H, Lopes J, Pinto HC, Marinho R, Raimundo M, Velosa J, Batista A, De Moura MC. Correlation of genotypes and route of transmission with histological activity and disease stage in chronic hepatitis C. Dig Dis Sci 2000;45:182-7.

  3. Poynard T, Bedossi P, Opson P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet 1997;349:825-32.

  4. Haque S, Chranda B, Gerber M, Lok A. Iron overload in patients with chronic hepatitis C: a clinicopathological study. Hum Pathol 1996;27:1377-81.

  5. Silini E, Bono F, Cividini A, Cerino A, Bruno S, Rossi S, Belloni G, Brugnetti R, Civardi E, Salvaneschi L, Mondelli MU. Differential distribution of hepatitis C genotypes in patients with and without liver function abnormalities. Hepatology 1995;2:285-90.

  6. Mangia I, Cascavilla G, Lezzi F, Spirito G, Maertens L, Parlatore G, Saracco N, Rizzetto N, Andriulli A. HCV genotypes in patients with liver disease of different stages and severity. J Hepatol 1997;26:1173-8.

  7. Negro F, Krawczynski K, Quadri R, Rubbia-Brandt L, Mondelli M, Zarski JP, Hadengue A. Detection of genomic and minus-strand of hepatitis C virus RNA in the liver of chronic hepatitis C patients by strand-specific semi-quantitative RTPCR. Hepatology 1999;29:536-42.

  8. Ostapowicz G, Watson KJR, Locarnini SA, Desmond PV. Role of alcohol in the progression of liver disease caused by hepatitis C virus infection. Hepatology 1998;27:1730-5.

  9. Goodman ZD, Ishak. KJ. Histopathology of hepatitis C virus infection. Semin Liver Dis 1995;15:70-81.

  10. Fischer HP, Willsch E, Bierhoff E, Pfeifer U. Histopathologic finding in chronic hepatitis C. J Hepatol 1996;24:35-42.

  11. Czaja AJ, Carpenter HA, Santrach PJ, Moore SR. Host and disease specific factors affecting steatosis in chronic hepatitis C. J Hepatol 1998;29:198-206.

  12. Clouston AD, Jonssom JR, Purdie DM, Macdonald GA, Pandeya N, Shorthouse C, Powell EE. Steatosis and chronic hepatitis C: analysis of fibrosis and stellate cell activation. J Hepatol 2001;34:314-20.

  13. Hourigan LF, MacDonald GA, Purdie GM, Whitehall VH, Shorthouse C, Clouston AD, Powell EE. Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis. Hepatology 1999;29:1215-9.

  14. Mihm S, Fayyazi A, Hartman H, Ramadori G. Analysis of histopathological manifestations of chronic hepatitis C virus infection with respect to virus genotype. Hepatology 1997;25:735-9.

  15. Rubbia-Brandt L, Quadri R, Abid K, Giostra E, Male PJ, Mentha G, Spahr L, Zarski JP, Borisch B, Hadengue A, Negro F. Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3. JHepatol 2000;33:106-15.

  16. Adinolfi L, Gambardella M, Andreana AAA, Tripodi M, Utili R, Ruggiero G. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotypes and visceral obesity. Hepatology 2001;33:1558-64.

  17. Serejo F, Costa A, Ramalho F, et al. Liver steatosis and HCV infection. Liver fibrosis. In: Proceedings of Cell Biology to Clinical Targets. Florence, Italy. 2001.

  18. Kumar D, Farrel G, Fung C, George G. Hepatitis C virus genotype 3 is cytopathic to hepatocytes: reversal of hepatic steatosis after sustained therapeutic response. Hepatology 2002;36:1266-72.

  19. Fujie H, Yotsuyanagi H, Murya K, Shintani Y, Tsutsumi T, Takayama T, Makuuchi M, Matsura Y, Miyamura T, Kimura S, Koike K. Steatosis and intrahepatic hepatitis C virus in chronic hepatitis. J Med Virol 1999;59:141-5.

  20. Abid K, Rossi C, Latorre P, Rubbia-Brandt L, Hadengue A, Negro F. The core protein of HCV genotype 3a, 3b and 1b induces lipid accumulation in Huh 7 cells. In: Proceedings of the 9th International Meeting on HCV and Related Viruses. San Diego, CA, USA. July 7-11, 2002.

  21. Moriya K, Yotsuyanagi H, Shintam H, Fujie H, Ishibasha K, Matsuura Y, Miyamura T, Koike K. Hepatitis C virus core protein induces steatosis in transgenic mice. J Gen Virol 1997;78:1527-31.

  22. Serfaty L, Andreani T, Giral P, Carbonnel N, Chazovillieres O, Poupon R. Hepatic virus induced hypobetaliproteinemia: a possible mechanism for steatosis in chronic hepatitis C. J Hepatol 2001;34:428-31.

  23. Ong JP, Younossi ZM, Speer C, Olano A, Gralmich T, Bopara N. Chronic hepatitis C and superimposed non alcoholic fatty liver disease. Liver 2001;21:266-271.

  24. Emerit i, Serejo F, Filipe P, Alaoui Youseefi A, Fernández, Costa A, Freitas J, Ramalho F, Bapista A, Carneiro de Mura A. Clastogenic factors as biomarkers of oxidative stress in chronic hepatitis C. Digestion 2000;62:200-7.

  25. DeMaria N, Calantroni A, Faginoli S, Guang-Jun L, Rogers BK, Farinati F, Van Thiel DH, Floyd RA. Association between reactive oxygen species and disease activity in chronic hepatitis C. Free Radic Biol Med 1996;21:291-5.

  26. Lee KS, Buck M, Houglum K, Chojkier M. Activation of hepatic stellate cells by TGF alpha and collagen type I mediated by oxidative stress through c-myc expression. J Clin Invest 1995;96:2461-8.




2020     |     www.medigraphic.com